process fixture 외부 mutation 계수 분리
日本語の概要は準備中です。原文の説明を表示しています。
367 件 ・ 関連度順
概要と使いどころ
process fixture 외부 mutation 계수 분리
日本語の概要は準備中です。原文の説明を表示しています。
Identify recurrent and driver copy number alterations across a tumor cohort with GISTIC2 (G-score, Ziggurat deconstruction, focal vs broad/arm-level analysis, q-values from permutation) and quantify copy-number signatures with the Steele 2022 COSMIC framework and the Drews 2022 CINSignatures framework. Covers driver-gene localization from recurrence peaks, distinguishing focal drivers from arm-level passengers, and the caller-sensitivity caveats of copy-number signatures. Use when finding recurrently amplified or deleted regions in a cohort, localizing driver genes, separating focal from broad events, running GISTIC2, or extracting copy-number mutational signatures.
日本語の概要は準備中です。原文の説明を表示しています。
Calculates tumor mutational burden from WES/WGS/panel data with Friends of Cancer Research harmonization equations, per-assay calibration (FDA 10/Mb = 7.8 TSO500 = 8.4 OncomineTML), synonymous/indel/germline filtering, hypermutator tiering, blood TMB, and integration with HLA-LOH and neoantigen quality (Luksza 2017 fitness). Use when assessing ICI eligibility under tumor-specific cutoffs (McGrail 2021), comparing tissue vs bTMB, or auditing TMB-H reporting against ESMO 2024 and FDA pembrolizumab pan-tumor 2020.
日本語の概要は準備中です。原文の説明を表示しています。
Extracts and assigns COSMIC v3.4 mutational signatures (86 SBS / 11 DBS / 18 ID / 21 CN / 16 SV) from somatic VCFs using SigProfilerSuite, MutationalPatterns, MuSiCal mvNMF, SigNet, or HRDetect. Use when characterizing DNA-damage etiology (BRCA1/2 HRD, MMR-D, POLE, APOBEC3A, UV, tobacco, aflatoxin, 5-FU/SBS17b, platinum, colibactin SBS88), routing PARP inhibitor decisions, or auditing de novo extraction vs refit choice for cohort size.
日本語の概要は準備中です。原文の説明を表示しています。
Expert-level genetics covering Mendelian inheritance, molecular genetics, mutations, linkage analysis, population genetics, epigenetics, and GWAS. Covers classical and modern approaches from Mendel to CRISPR.
日本語の概要は準備中です。原文の説明を表示しています。
Turn surviving mutants into better tests, or into bug reports. Use when a mutation run reports escaped mutants, when the MSI gate fails, when asked whether a test suite is actually testing anything, or before proposing to lower a threshold.
日本語の概要は準備中です。原文の説明を表示しています。
Mutation testing patterns for verifying test effectiveness. Use when analyzing branch code to find weak or missing tests.
日本語の概要は準備中です。原文の説明を表示しています。
Review someone else's pull request by measuring which of its own guards its own test suite actually catches, via a small mutation matrix. Use when reviewing a PR, checking whether a regression test is real, or asked 'is this change actually tested?', 'does this test do anything', 'mutation test this'.
日本語の概要は準備中です。原文の説明を表示しています。
Performs GraphQL introspection attacks to Şunu çıkar: full API schema including types, queries, mutations, subscriptions, and field definitions from GraphQL endpoints. The tester uses introspection queries to map the attack surface, identifies sensitive fields and mutations, tests for query depth and complexity limits, and exploits GraphQL-specific vulnerabilities including batching attacks, alias-based brute force, and nested query DoS. Activates for requests involving GraphQL security testi...
日本語の概要は準備中です。原文の説明を表示しています。
Orchestrates an end-to-end immune-repertoire pipeline from FASTQ to clonotypes, diversity, overlap, somatic hypermutation and lineages, routing on two forks. Use when deciding bulk vs single-cell (bulk amplicon/RNA-seq -> MiXCR analyze preset -> VDJtools/immunarch depth-normalized diversity and overlap -> figures; 10x paired VDJ -> MiXCR 10x preset or Cell Ranger -> scirpy gene-expression integration, chain QC, clonotype clusters); and TCR vs BCR (TCR -> exact CDR3-nt+V/J clonotypes, VDJtools diversity is fine; BCR -> somatic hypermutation makes exact clonotypes wrong -> Immcantation distToNearest/findThreshold clonal clustering, germline reconstruction, SHM, Dowser lineages); selecting the MiXCR 4.x preset by chemistry and activating its license; downsampling to equal depth before comparing diversity or overlap; and optionally annotating antigen specificity.
日本語の概要は準備中です。原文の説明を表示しています。
TanStack Query (React Query) v5 (@tanstack/react-query) の API リファレンス。 useQuery, useQueries, useInfiniteQuery, useMutation, useSuspenseQuery, QueryClient, QueryClientProvider, queryOptions, HydrationBoundary, invalidateQueries, prefetchQuery, staleTime, gcTime, placeholderData, optimistic updates, SSR / hydration, persistQueryClient, eslint-plugin-query。 kubb(フック生成側)とは別。
Designs donor/repair templates for precise CRISPR knock-ins -- choosing the format (ssODN, long-ssDNA/Easi-CRISPR, dsDNA/plasmid, AAV6), sizing homology arms, placing the cut within ~10 bp of the edit, and adding a mandatory codon-checked blocking (PAM/seed) mutation so the edited allele is not re-cut. Frames the HDR-vs-NHEJ-vs-MMEJ pathway competition, the MMEJ (PITCh) and homology-independent (HITI/HMEJ) alternatives for post-mitotic cells, ssODN strand/asymmetry choice, phosphorothioate end-protection, and ranked HDR enhancers. Use when designing a donor for a point mutation, epitope/fluorophore tag, allele replacement, or knock-in, or when HDR efficiency is low. Guide design and base/prime editing are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Identify recurrent and driver copy number alterations across a tumor cohort with GISTIC2 (G-score, Ziggurat deconstruction, focal vs broad/arm-level analysis, q-values from permutation) and quantify copy-number signatures with the Steele 2022 COSMIC framework and the Drews 2022 CINSignatures framework. Covers driver-gene localization from recurrence peaks, distinguishing focal drivers from arm-level passengers, and the caller-sensitivity caveats of copy-number signatures. Use when finding recurrently amplified or deleted regions in a cohort, localizing driver genes, separating focal from broad events, running GISTIC2, or extracting copy-number mutational signatures.
日本語の概要は準備中です。原文の説明を表示しています。
Extracts and assigns COSMIC v3.4 mutational signatures (84 SBS / 11 DBS / 18 ID / 24 CN / 16 SV) from somatic VCFs using SigProfilerSuite, MutationalPatterns, MuSiCal mvNMF, SigNet, or HRDetect. Use when characterizing DNA-damage etiology (BRCA1/2 HRD, MMR-D, POLE, APOBEC3A, UV, tobacco, aflatoxin, 5-FU/SBS17b, platinum, colibactin SBS88), routing PARP inhibitor decisions, or auditing de novo extraction vs refit choice for cohort size.
日本語の概要は準備中です。原文の説明を表示しています。
Calculates tumor mutational burden from WES/WGS/panel data with Friends of Cancer Research harmonization equations, per-assay calibration (FDA 10/Mb = 7.8 TSO500 = 8.4 OncomineTML), synonymous/indel/germline filtering, hypermutator tiering, blood TMB, and integration with HLA-LOH and neoantigen quality (Luksza 2017 fitness). Use when assessing ICI eligibility under tumor-specific cutoffs (McGrail 2021), comparing tissue vs bTMB, or auditing TMB-H reporting against ESMO 2024 and FDA pembrolizumab pan-tumor 2020.
日本語の概要は準備中です。原文の説明を表示しています。
Performs simple mutation testing to verify test coverage and assertions.
日本語の概要は準備中です。原文の説明を表示しています。
Spec-locked TDD with a mutation-testing gate — refine the intent into an immutable Gherkin contract (SHA-256 frozen), implement under the three laws of TDD, pass a judge audit, and merge only if every mutant dies.
日本語の概要は準備中です。原文の説明を表示しています。
Build real-time, reactive backend applications with Convex using TypeScript queries, mutations, and actions with automatic reactivity and optimistic updates. Use when building real-time collaborative applications, implementing reactive data synchronization, writing serverless backend functions, creating queries that auto-update, implementing mutations with transactional guarantees, handling file uploads with Convex storage, implementing authentication with Convex Auth, designing reactive database schemas, or building applications requiring instant data synchronization.
日本語の概要は準備中です。原文の説明を表示しています。
Designs donor/repair templates for precise CRISPR knock-ins -- choosing the format (ssODN, long-ssDNA/Easi-CRISPR, dsDNA/plasmid, AAV6), sizing homology arms, placing the cut within ~10 bp of the edit, and adding a mandatory codon-checked blocking (PAM/seed) mutation so the edited allele is not re-cut. Frames the HDR-vs-NHEJ-vs-MMEJ pathway competition, the MMEJ (PITCh) and homology-independent (HITI/HMEJ) alternatives for post-mitotic cells, ssODN strand/asymmetry choice, phosphorothioate end-protection, and ranked HDR enhancers. Use when designing a donor for a point mutation, epitope/fluorophore tag, allele replacement, or knock-in, or when HDR efficiency is low. Guide design and base/prime editing are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Identify recurrent and driver copy number alterations across a tumor cohort with GISTIC2 (G-score, Ziggurat deconstruction, focal vs broad/arm-level analysis, q-values from permutation) and quantify copy-number signatures with the Steele 2022 COSMIC framework and the Drews 2022 CINSignatures framework. Covers driver-gene localization from recurrence peaks, distinguishing focal drivers from arm-level passengers, and the caller-sensitivity caveats of copy-number signatures. Use when finding recurrently amplified or deleted regions in a cohort, localizing driver genes, separating focal from broad events, running GISTIC2, or extracting copy-number mutational signatures.
日本語の概要は準備中です。原文の説明を表示しています。
Calculates tumor mutational burden from WES/WGS/panel data with Friends of Cancer Research harmonization equations, per-assay calibration (FDA 10/Mb = 7.8 TSO500 = 8.4 OncomineTML), synonymous/indel/germline filtering, hypermutator tiering, blood TMB, and integration with HLA-LOH and neoantigen quality (Luksza 2017 fitness). Use when assessing ICI eligibility under tumor-specific cutoffs (McGrail 2021), comparing tissue vs bTMB, or auditing TMB-H reporting against ESMO 2024 and FDA pembrolizumab pan-tumor 2020.
日本語の概要は準備中です。原文の説明を表示しています。
Extracts and assigns COSMIC v3.4 mutational signatures (84 SBS / 11 DBS / 18 ID / 24 CN / 16 SV) from somatic VCFs using SigProfilerSuite, MutationalPatterns, MuSiCal mvNMF, SigNet, or HRDetect. Use when characterizing DNA-damage etiology (BRCA1/2 HRD, MMR-D, POLE, APOBEC3A, UV, tobacco, aflatoxin, 5-FU/SBS17b, platinum, colibactin SBS88), routing PARP inhibitor decisions, or auditing de novo extraction vs refit choice for cohort size.
日本語の概要は準備中です。原文の説明を表示しています。
Hunting skill for graphql vulnerabilities. Built from 12 public bug bounty reports across IDOR via node() / GID, mutation IDOR including AI/LLM features, cross-tenant IDOR, SSRF via argument, batching-DoS, query-cost-bypass, SQLi via argument, broken-object-level-authz, auth-bypass via unscoped mutations, and PII exposure from missing field-level authz. Use when hunting graphql on any target.
日本語の概要は準備中です。原文の説明を表示しています。
Refute-before-prove research discipline: automated counterexample sweeps before any formalization, meter-integrity audits for information-bound experiments, mutation-tested model checkers, pre-registered commit-or-cut gates for speculative directions, wrong-turn reporting, and numeric-claim provenance. Use when validating any new theorem, bound, equilibrium, or security claim; when building or trusting a checker, simulator, or experiment; or when deciding whether a speculative research direction lives or dies. NOT for exploratory brainstorming, product prioritization, writing style, or literature review.
日本語の概要は準備中です。原文の説明を表示しています。